Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
American Journal of Human Genetics|April 13, 2004
Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the worldToshiaki Nakajima, Stephen Wooding, Takuro Sakagami, et al.
Scientific Reports|October 9, 2021
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumoniaKazuya Ichikado, Kodai Kawamura, Takeshi Johkoh, et al.
American Journal of Respiratory and Critical Care Medicine|March 13, 2010
Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primatesTakuro Sakagami, David Beck, Kanji Uchida, et al.
The Journal of Experimental Medicine|October 29, 2008
Familial pulmonary alveolar proteinosis caused by mutations in CSF2RATakuji Suzuki, Takuro Sakagami, Bruce K Rubin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2021
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)Yoshihiko Sakata, Shinya Sakata, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT studyAsuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
Clinical Lung Cancer|June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Clinical Pharmacology and Therapeutics|June 18, 2024
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and OlderShigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, et al.
Science Translational Medicine|December 14, 2022
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancerKentaro Tanaka, Kenji Chamoto, Sho Saeki, et al.
Pageof 17